The role of CDK4/6 inhibitors in early breast cancer by Miguel Gil-Gil, Emilio Alba, Joaquín Gavilá, Juan de la Haba-Rodríguez, Eva Ciruelos, Pablo Tolosa, Daniele Candini, Antonio Llombart-Cussac

Get full text

582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1... by Kevin Kelly, Matt Coffey, Tomás Pascual, Aleix Prat, Luis Manso, Thomas Heineman, Fernando Salvador, Joaquín Gavilá, Houra Loghmani, Richard Trauger, Akil Merchant, Julian Olea, Homa Dadrastoussi, Eduardo Fernandez Hernandez, Hugo Lara Martinez, Kaijin Wu

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy by Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou

Get full text

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy by Nuria Chic, Francesco Schettini, Fara Brasó-Maristany, Esther Sanfeliu, Barbara Adamo, Maria Vidal, Débora Martínez, Patricia Galván, Blanca González-Farré, Javier Cortés, Joaquín Gavilá, Cristina Saura, Mafalda Oliveira, Sònia Pernas, Olga Martínez-Sáez, Jesús Soberino, Eva Ciruelos, Lisa A. Carey, Montserrat Muñoz, Charles M. Perou, Tomás Pascual, Meritxell Bellet, Aleix Prat

Get full text

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer by Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Isabel Garcia-Fructuoso, Adela Rodríguez, Raquel Gómez-Bravo, Francesco Schettini, Paula Blasco, Oleguer Castillo, Blanca González-Farré, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Marcos Malumbres, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Fara Brasó-Maristany

Get full text

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer by Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac

Get full text

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer by Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon

Get full text

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer by Tomás Pascual, Tomás Pascual, Tomás Pascual, Mafalda Oliveira, Mafalda Oliveira, Mafalda Oliveira, Eva Ciruelos, Eva Ciruelos, Meritxell Bellet Ezquerra, Meritxell Bellet Ezquerra, Meritxell Bellet Ezquerra, Cristina Saura, Cristina Saura, Cristina Saura, Joaquin Gavilá, Joaquin Gavilá, Sonia Pernas, Sonia Pernas, Montserrat Muñoz, Montserrat Muñoz, Montserrat Muñoz, Maria J. Vidal, Maria J. Vidal, Maria J. Vidal, Mireia Margelí Vila, Mireia Margelí Vila, Juan M. Cejalvo, Juan M. Cejalvo, Blanca González-Farré, Blanca González-Farré, Blanca González-Farré, Martin Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Guillermo Villacampa, Laia Paré, Juan M. Ferrero-Cafiero, Patricia Villagrasa, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat

Get full text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

Get full text

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

Get full text

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication by Meritxell Bellet, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquín Gavilá, Santiago Escrivá-de-Romaní, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Pilar Zamora, Victoria Reyes, María Alcalde, Helena Masanas, Pamela Céliz, Isabel Ruíz, Miguel Gil, Miguel Àngel Seguí, Lorena de la Peña

Get full text

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with... by Rubén Olivera-Salguero, Elia Seguí, Elia Seguí, Elia Seguí, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Mafalda Oliveira, Mafalda Oliveira, Mafalda Oliveira, Pablo Tolosa, Pablo Tolosa, Maria Vidal, Maria Vidal, Maria Vidal, Maria Vidal, Marcos Malumbres, Marcos Malumbres, Marcos Malumbres, Joaquín Gavilá, Joaquín Gavilá, Cristina Saura, Cristina Saura, Sonia Pernas, Sonia Pernas, Rafael López, Rafael López, Mireia Margelí, Mireia Margelí, Judith Balmaña, Judith Balmaña, Montserrat Muñoz, Montserrat Muñoz, Montserrat Muñoz, Isabel Blancas, Isabel Blancas, Valentina Boni, Valentina Boni, Eva Ciruelos, Eva Ciruelos, Eva Ciruelos, Elena Galve, Elena Galve, Antonia Perelló, Antonia Perelló, Rodrigo Sánchez-Bayona, Rodrigo Sánchez-Bayona, Susana de la Cruz, Susana de la Cruz, Miguel de la Hoya, Patricia Galván, Esther Sanfeliu, Esther Sanfeliu, Esther Sanfeliu, Blanca Gonzalez-Farre, Blanca Gonzalez-Farre, Blanca Gonzalez-Farre, Valeria Sirenko, Aura Blanch-Torras, Jordi Canes, Helena Masanas, Rosa Olmos, Margarita Forns, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat, Ana Casas, Ana Casas, Tomás Pascual, Tomás Pascual

Get full text

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin

Get full text